SARS-CoV-2-specific Humoral Immune Responses after A Single dose of Inactivated Whole-virus SARS-CoV-2 Vaccine in Kidney Transplant Recipients: An Initial Report

Abstract

We presented an initial pilot study report focused on immunogenicity and safety following an inactivated whole virus severe acute respiratory syndrome coronavirus 2 vaccination among kidney transplant (KT) recipients. At four weeks after the first dose of vaccine, the level of anti RBD IgG antibody was not significantly different compared to before vaccination in 30 KT recipients (p = 0.45). Moreover, a significant lower mean (95% CI) anti RBD IgG antibody was observed compared to 30 immunocompetent controls (2.4 [95% CI 1.3 to 3.5] vs. 173.1 [95% CI 88.3-2,457.9] AU/mL, p < 0.001). Mild adverse events included fever (17%) and localized pain at the injection site (14%) were observed after vaccination.

Real-world Evidence of COVID-19 Vaccines Effectiveness in Solid-organ Transplant Recipient Population in Colombia: A Study Nested in the Esperanza Cohort

“…3 It is worth noting that all 5 vaccines were used in the SOTR population because no specific vaccine platform was determined for them. 4 SOTRs are more prone to a SARS-CoV-2 infection because of their immunosuppression and their lower likelihood to develop an effective immune response to vaccination [5][6][7][8][9][10][11] because their immune response to natural infection is also less powerful and lasting, rendering them more vulnerable to reinfections. 12 Additionally, chronic immunosuppression might reduce the infectious dose necessary to cause COVID-19 and hinder the immune control once the infection has been established, which increases the risk of severe infection and complications.…”